dolby laboratories inc - DLB
DLB
Close Chg Chg %
80.33 0.01 0.01%
Closed Market
80.34
+0.01 (0.01%)
Volume: 464.85K
Last Updated:
Nov 26, 2024, 3:59 PM EDT
Company Overview: dolby laboratories inc - DLB
DLB Key Data
| Open $80.26 | Day Range 79.69 - 81.20 |
| 52 Week Range 66.35 - 90.06 | Market Cap $7.66B |
| Shares Outstanding 95.44M | Public Float 58.76M |
| Beta 0.98 | Rev. Per Employee N/A |
| P/E Ratio 29.85 | EPS $2.74 |
| Yield 149.44% | Dividend $0.33 |
| EX-DIVIDEND DATE Dec 3, 2024 | SHORT INTEREST N/A |
| AVERAGE VOLUME 436.91K |
DLB Performance
| 1 Week | -0.27% | ||
| 1 Month | 10.36% | ||
| 3 Months | 12.57% | ||
| 1 Year | -7.09% | ||
| 5 Years | 16.62% |
DLB Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About dolby laboratories inc - DLB
Dolby Laboratories, Inc. engages in the provision of audio and imaging technologies. It operates through the United States and International geographical segments. The company was founded by Ray Milton Dolby in 1965 and is headquartered in San Francisco, CA.
DLB At a Glance
Dolby Laboratories, Inc.
1275 Market Street
San Francisco, California 94103-1410
| Phone | 1-415-558-0200 | Revenue | 1.27B | |
| Industry | Packaged Software | Net Income | 261.83M | |
| Sector | Technology Services | Employees | 2,080 | |
| Fiscal Year-end | 09 / 2025 | |||
| View SEC Filings |
DLB Valuation
| P/E Current | 29.849 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 28.106 |
| Price to Sales Ratio | 5.777 |
| Price to Book Ratio | 2.912 |
| Price to Cash Flow Ratio | 22.487 |
| Enterprise Value to EBITDA | 19.423 |
| Enterprise Value to Sales | 5.368 |
| Total Debt to Enterprise Value | 0.007 |
DLB Efficiency
| Revenue/Employee | 612,365.865 |
| Income Per Employee | 125,877.404 |
| Receivables Turnover | 2.483 |
| Total Asset Turnover | 0.416 |
DLB Liquidity
| Current Ratio | 2.859 |
| Quick Ratio | 2.778 |
| Cash Ratio | 1.383 |
DLB Profitability
| Gross Margin | 88.97 |
| Operating Margin | 20.782 |
| Pretax Margin | 24.533 |
| Net Margin | 20.556 |
| Return on Assets | 8.549 |
| Return on Equity | 10.837 |
| Return on Total Capital | 10.373 |
| Return on Invested Capital | 10.678 |
DLB Capital Structure
| Total Debt to Total Equity | 1.897 |
| Total Debt to Total Capital | 1.862 |
| Total Debt to Total Assets | 1.501 |
| Long-Term Debt to Equity | 1.403 |
| Long-Term Debt to Total Capital | 1.377 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Dolby Laboratories Inc - DLB
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.28B | 1.25B | 1.30B | 1.27B | |
Sales Growth
| +10.28% | -2.14% | +3.66% | -2.00% | |
Cost of Goods Sold (COGS) incl D&A
| 130.03M | 141.36M | 152.57M | 140.50M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 95.86M | 103.61M | 95.51M | 87.33M | |
Depreciation
| 66.36M | 74.61M | 66.91M | 54.13M | |
Amortization of Intangibles
| 29.50M | 29.00M | 28.60M | 33.20M | |
COGS Growth
| -11.24% | +8.72% | +7.93% | -7.91% | |
Gross Income
| 1.15B | 1.11B | 1.15B | 1.13B | |
Gross Income Growth
| +13.39% | -3.37% | +3.12% | -1.22% | |
Gross Profit Margin
| +89.85% | +88.73% | +88.26% | +88.97% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 810.47M | 895.21M | 884.36M | 868.51M | |
Research & Development
| 253.64M | 261.17M | 271.52M | 263.66M | |
Other SG&A
| 556.83M | 634.03M | 612.84M | 604.85M | |
SGA Growth
| +1.98% | +10.45% | -1.21% | -1.79% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 10.24M | 10.62M | 47.06M | 6.38M | |
EBIT after Unusual Expense
| 330.52M | 206.61M | 215.75M | 258.33M | |
Non Operating Income/Expense
| 23.99M | 8.67M | 34.30M | 54.15M | |
Non-Operating Interest Income
| 3.49M | 6.57M | 28.09M | 34.08M | |
Equity in Earnings of Affiliates
| - | - | 5.10M | 14.20M | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 354.51M | 215.28M | 250.05M | 312.48M | |
Pretax Income Growth
| +47.89% | -39.27% | +16.15% | +24.97% | |
Pretax Margin
| +27.67% | +17.17% | +19.24% | +24.53% | |
Income Tax
| 36.69M | 31.38M | 48.41M | 48.16M | |
Income Tax - Current - Domestic
| 8.17M | 2.56M | (30.00K) | 1.83M | |
Income Tax - Current - Foreign
| 65.57M | 58.28M | 66.78M | 68.01M | |
Income Tax - Deferred - Domestic
| (36.10M) | (29.98M) | (17.30M) | (21.31M) | |
Income Tax - Deferred - Foreign
| (950.00K) | 517.00K | (1.03M) | (362.00K) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | 5.10M | 14.20M | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 317.82M | 183.90M | 201.64M | 264.32M | |
Minority Interest Expense
| 7.60M | (189.00K) | 988.00K | 2.49M | |
Net Income
| 310.23M | 184.09M | 200.66M | 261.82M | |
Net Income Growth
| +34.09% | -40.66% | +9.00% | +30.48% | |
Net Margin Growth
| +24.21% | +14.68% | +15.44% | +20.56% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 310.23M | 184.09M | 200.66M | 261.82M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 310.23M | 184.09M | 200.66M | 261.82M | |
EPS (Basic)
| 3.0658 | 1.841 | 2.0952 | 2.7404 | |
EPS (Basic) Growth
| +33.26% | -39.95% | +13.81% | +30.79% | |
Basic Shares Outstanding
| 101.19M | 99.99M | 95.77M | 95.54M | |
EPS (Diluted)
| 2.9652 | 1.8051 | 2.0531 | 2.6902 | |
EPS (Diluted) Growth
| +31.93% | -39.12% | +13.74% | +31.03% | |
Diluted Shares Outstanding
| 104.62M | 101.98M | 97.73M | 97.33M | |
EBITDA
| 436.62M | 320.84M | 358.33M | 352.04M | |
EBITDA Growth
| +40.19% | -26.52% | +11.69% | -1.76% | |
EBITDA Margin
| +34.08% | +25.59% | +27.57% | +27.64% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 99.00 | |
| Number of Ratings | 5 | Current Quarters Estimate | 0.605 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 2.52 | |
| Last Quarter’s Earnings | 0.61 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.69 | Next Fiscal Year Estimate | 2.87 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 2 | 2 | 2 | 1 |
| Mean Estimate | 0.61 | 0.98 | 2.52 | 2.87 |
| High Estimates | 0.62 | 1.11 | 2.56 | 2.87 |
| Low Estimate | 0.59 | 0.84 | 2.48 | 2.87 |
| Coefficient of Variance | 3.51 | 19.58 | 2.24 | N/A |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Dolby Laboratories Inc - DLB
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Dolby Laboratories Inc - DLB
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 26, 2024 | Kevin J. Yeaman President and CEO; Director | 3 | Open market or private purchase of non-derivative security Non-derivative transaction at $78.15 per share | 234.45 |
| May 31, 2024 | Mark Andrew Sherman EVP, Gen. Counsel & Secretary | 58,325 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $79.62 per share | 4,643,836.50 |
| May 31, 2024 | Mark Andrew Sherman EVP, Gen. Counsel & Secretary | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 31, 2024 | Mark Andrew Sherman EVP, Gen. Counsel & Secretary | 60,608 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $62.32 per share | 3,777,090.56 |
| Mar 6, 2024 | Emily Rollins Director | 7,493 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $80.88 per share | 606,033.84 |
| Feb 15, 2024 | Kevin J. Yeaman President and CEO; Director | 81,884 | Bona fide gift | 0.00 |
| Feb 13, 2024 | John Couling SVP, Entertainment | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 13, 2024 | John Couling SVP, Entertainment | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 13, 2024 | John Couling SVP, Entertainment | 12,440 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 13, 2024 | John Couling SVP, Entertainment | 108,519 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $80.81 per share | 8,769,420.39 |
| Feb 13, 2024 | John Couling SVP, Entertainment | 142,079 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $62.32 per share | 8,854,363.28 |
| Feb 13, 2024 | John Couling SVP, Entertainment | 120,959 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $42.98 per share | 5,198,817.82 |
| Feb 13, 2024 | John Couling SVP, Entertainment | 108,519 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $80 per share | 8,681,520.00 |
| Feb 13, 2024 | John Couling SVP, Entertainment | 158,519 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $42.98 per share | 6,813,146.62 |
| Feb 9, 2024 | Anjali Sud Director | 9,031 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 9, 2024 | Tony A. Prophet Director | 9,267 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 9, 2024 | Dave Dolby Director | 85,670 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 9, 2024 | Simon Anthony Segars Director | 40,102 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 9, 2024 | Avadis Tevanian Director | 2,952 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 9, 2024 | Peter C. Gotcher Director | 43,672 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |